141 related articles for article (PubMed ID: 12503693)
1. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate.
Austin RJ; Maschera B; Walker A; Fairbairn L; Meldrum E; Farrow SN; Uings IJ
Eur Respir J; 2002 Dec; 20(6):1386-92. PubMed ID: 12503693
[TBL] [Abstract][Full Text] [Related]
2. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.
Crim C; Pierre LN; Daley-Yates PT
Clin Ther; 2001 Sep; 23(9):1339-54. PubMed ID: 11589253
[TBL] [Abstract][Full Text] [Related]
3. Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies.
Roumestan C; Henriquet C; Bousquet J; Mathieu M
Clin Exp Allergy; 2003 Jul; 33(7):895-901. PubMed ID: 12859444
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone furoate is more effective than mometasone furoate in restoring tobacco smoke inhibited SOCS-3 expression in airway epithelial cells.
Nasreen N; Gonzalves L; Peruvemba S; Mohammed KA
Int Immunopharmacol; 2014 Mar; 19(1):153-60. PubMed ID: 24434372
[TBL] [Abstract][Full Text] [Related]
6. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.
Tayab ZR; Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ; Hochhaus G
Br J Clin Pharmacol; 2007 Nov; 64(5):698-705. PubMed ID: 17509041
[TBL] [Abstract][Full Text] [Related]
8. Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.
Zhang N; Van Crombruggen K; Holtappels G; Lan F; Katotomichelakis M; Zhang L; Högger P; Bachert C
PLoS One; 2014; 9(4):e93754. PubMed ID: 24710117
[TBL] [Abstract][Full Text] [Related]
9. Development of fluticasone propionate and comparison with other inhaled corticosteroids.
Johnson M
J Allergy Clin Immunol; 1998 Apr; 101(4 Pt 2):S434-9. PubMed ID: 9563368
[TBL] [Abstract][Full Text] [Related]
10. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.
Mandl M; Nolop K; Lutsky BN
Ann Allergy Asthma Immunol; 1997 Sep; 79(3):237-45. PubMed ID: 9305231
[TBL] [Abstract][Full Text] [Related]
11. Effect of mometasone furoate by topical application on allergic rhinitis model in rats.
Sugimoto Y; Ishizawa K; Saitou K; Suzuki G; Tarumi T; Nakahara H; Kirino Y; Kamei C
Pharmacology; 2000 Aug; 61(2):91-5. PubMed ID: 10940782
[TBL] [Abstract][Full Text] [Related]
12. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
[TBL] [Abstract][Full Text] [Related]
13. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis.
Lumry WR
J Allergy Clin Immunol; 1999 Oct; 104(4 Pt 1):S150-8. PubMed ID: 10518812
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis.
Mak KK; Ku MS; Lu KH; Sun HL; Lue KH
Pediatr Neonatol; 2013 Aug; 54(4):239-45. PubMed ID: 23597528
[TBL] [Abstract][Full Text] [Related]
15. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.
Valotis A; Högger P
Respir Res; 2007 Jul; 8(1):54. PubMed ID: 17650349
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
Wardlaw A; Larivee P; Eller J; Cockcroft DW; Ghaly L; Harris AG
Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
Daley-Yates PT; Kunka RL; Yin Y; Andrews SM; Callejas S; Ng C
Eur J Clin Pharmacol; 2004 Jun; 60(4):265-8. PubMed ID: 15114430
[TBL] [Abstract][Full Text] [Related]
18. Fluticasone propionate and mometasone furoate have a low risk of contact sensitization.
Wilkinson SM; Beck MH
Contact Dermatitis; 1996 May; 34(5):365-6. PubMed ID: 8807234
[No Abstract] [Full Text] [Related]
19. Characterization of degradation products of mometasone furoate.
Sahasranaman S; Issar M; Tóth G; Horváth G; Hochhaus G
Pharmazie; 2004 May; 59(5):367-73. PubMed ID: 15212303
[TBL] [Abstract][Full Text] [Related]
20. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate.
Valotis A; Neukam K; Elert O; Högger P
J Pharm Sci; 2004 May; 93(5):1337-50. PubMed ID: 15067709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
